clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-71-74clinvest-531Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность и перспективы применения препарата колхицин у пациентов с COVID-19Current and future use of colchicine in patients with COVID-19https://orcid.org/0000-0002-6753-8572КиселёвЮ. Ю.KiselevYu. Yu.

Киселёв Юрий Юрьевич – PhD, доцент факультета наук о здоровье OsloMet

Осло

Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet

Oslo

https://orcid.org/0000-0002-6636-3950МатвеевА. В.MatveevA. V.

Матвеев Александр Витальевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8518-1320

Москва

Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comУниверситет Осло МетрополитенНорвегияOslo Metropolitan UniversityNorwayФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID7174Copyright © Киселёв Ю.Ю., Матвеев А.В., Сычёв Д.А., 20202020Киселёв Ю.Ю., Матвеев А.В., Сычёв Д.А.Kiselev Y.Y., Matveev A.V., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/531

Существуют теоретические предпосылки к применению колхицина в лечении пациентов с COVID-19, ведутся клинические исследования. На сегодня отсутствуют опубликованные данные, подтверждающих эффективность и безопасность применения колхицина при COVID-19 и позволяющие рекомендовать его для широкой практики. При использовании колхицина важно осуществлять клинический и гематологический контроль и избегать лекарственных взаимодействий.

There exist some theoretical premises for the use of colchicine in patients with COVID-19, and clinical trials are underway. There is currently no published evidence confirming effectiveness and safety of colchicine in COVID-19 and allowing to recommend it for general practice. If prescribing colchicine, the one should perform clinical and hematological monitoring and avoid drug interactions.

коронавирусколхицинCOVID-19coronaviruscolchicineCOVID-19Referenceshttps://grls.rosminzdrav.ru/https://grls.rosminzdrav.ru/https://www.medicines.org.uk/emc/product/6415/smpchttps://www.medicines.org.uk/emc/product/6415/smpcMisawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013 May;14(5):454-60. DOI: 10.1038/ni.2550Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013 May;14(5):454-60. DOI: 10.1038/ni.2550Hemkens LG, Ewald H, Gloy VL et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016 Jan 27;2016(1):CD011047. DOI: 10.1002/14651858.CD011047.pub2Hemkens LG, Ewald H, Gloy VL et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016 Jan 27;2016(1):CD011047. DOI: 10.1002/14651858.CD011047.pub2Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of LowDose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. DOI: 10.1056/NEJMoa1912388Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of LowDose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. DOI: 10.1056/NEJMoa1912388Leung YY, Hui LLY, Kraus VB. Colchicine-update on mechanism of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341-50. DOI: 10.1016/j.semarthrit.2015.06.013Leung YY, Hui LLY, Kraus VB. Colchicine-update on mechanism of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341-50. DOI: 10.1016/j.semarthrit.2015.06.013Milewska A, Nowak P, Owczarek K et al. Entry of human coronavirus NL63 into the cell. J Virol. 2018;92:e01933-17. DOI: 10.1128/JVI.01933-17Milewska A, Nowak P, Owczarek K et al. Entry of human coronavirus NL63 into the cell. J Virol. 2018;92:e01933-17. DOI: 10.1128/JVI.01933-17Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64(12):1420-3Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64(12):1420-3Piantoni S, Patroni A, Toniati P et al. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease [Access publication 2020 May 30]. Rheumatology (Oxford). 2020;59:1769-1770. DOI: 10.1093/rheumatology/keaa217Piantoni S, Patroni A, Toniati P et al. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease [Access publication 2020 May 30]. Rheumatology (Oxford). 2020;59:1769-1770. DOI: 10.1093/rheumatology/keaa217Nasiripour S, Zamani F, Farasatinasab M. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? [Access publication 2020 May 23]. J Clin Pharmacol. 2020 Jul;60(7):828-829. DOI: 10.1002/jcph.1645Nasiripour S, Zamani F, Farasatinasab M. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? [Access publication 2020 May 23]. J Clin Pharmacol. 2020 Jul;60(7):828-829. DOI: 10.1002/jcph.1645https://covid19evidence.net.au/https://covid19evidence.net.au/https://www.covid19treatmentguidelines.nih.gov/https://www.covid19treatmentguidelines.nih.gov/https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdfhttps://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdfhttps://www.canada.ca/en/public-health/services/diseases/2019-novelcoronavirus-infection/clinical-management-covid-19.htmlhttps://www.canada.ca/en/public-health/services/diseases/2019-novelcoronavirus-infection/clinical-management-covid-19.htmlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/pdf/idr-121-8543.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/pdf/idr-121-8543.pdfhttp://mc.msu.ru/protokol-COVID-MNOC.pdf?fbclid=IwAR0pcfEk_LpYL8O6YKNGEbe3b_FuEpYTbiap8JTH6ZhnVjYLzTFtHBKpYNYhttp://mc.msu.ru/protokol-COVID-MNOC.pdf?fbclid=IwAR0pcfEk_LpYL8O6YKNGEbe3b_FuEpYTbiap8JTH6ZhnVjYLzTFtHBKpYNYDella-Torre E, Della-Torre F, Kusanovic Pcp M et al. Treating COVID-19 with colchicine in community healthcare setting [Access publication 2020 May 31]. Clin Immunol. 2020 Aug;217:108490. DOI: 10.1016/j.clim.2020.108490Della-Torre E, Della-Torre F, Kusanovic Pcp M et al. Treating COVID-19 with colchicine in community healthcare setting [Access publication 2020 May 31]. Clin Immunol. 2020 Aug;217:108490. DOI: 10.1016/j.clim.2020.108490Cumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? [Access publication 2020 May 11]. Clin Rheumatol. 2020 Jul;39(7):2101-2102. DOI:10.1007/s10067-02005144-xCumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? [Access publication 2020 May 11]. Clin Rheumatol. 2020 Jul;39(7):2101-2102. DOI:10.1007/s10067-02005144-xGendelman O, Amital H, Bragazzi NL et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020 Jul;19(7):102566. DOI: 10.1016/j.autrev.2020.102566Gendelman O, Amital H, Bragazzi NL et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020 Jul;19(7):102566. DOI: 10.1016/j.autrev.2020.102566https://www.fda.gov/drugs/postmarket-drug-safety-information-patientsand-providers/colchicine-marketed-colcrys-informationhttps://www.fda.gov/drugs/postmarket-drug-safety-information-patientsand-providers/colchicine-marketed-colcrys-informationhttps://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=

The authors declare that there are no conflicts of interest present.